+1 (202) 780-3397
Perspective - Journal of Molecular Oncology Research (2023) Volume 7, Issue 1
Approaches of chronic myelogenous leukemia
Modern clinical therapy of chronic myeloid leukemia with TKIs is highly efficacious in most CML patients, while it is not remedial and generally confined due to intolerance or resistance. CML is currently considered a severe disease. Interestingly, stem cell transplantation in the past decade was an attractive clinical therapeutic option in CML patients, but it is not successful due to independently more death rates in older patients. So, the targeting of BCR::ABL oncoprotein is extensively used to enhance the reduction in a higher percentage of CML patients by tyrosine kinase inhibitors.
Author(s): Norma Cohen